Search
Personalis Inc
PSNLAdd to Watchlist
12.660USD
+0.380+3.09%
Close 07-31 16:00（ET）Quotes delayed by 15 min
1.35BMarket Cap
LossP/E TTM
More Details of Personalis Inc Company
Personalis, Inc. is engaged in developing, marketing and selling advanced cancer genomic tests and analytics. The Company’s advanced genomic sequencing and analytics support the development of personalized cancer vaccines and other cancer immunotherapies. Its products include NeXT Personal, ImmunoI DNeXT, NeXT Personal Dx, NeXT Dx, whole exome sequencing (WES), and whole genome sequencing (WGS). NeXT Personal is a tumor-informed liquid biopsy test for the detection of minimal residual disease (MRD) and recurrence in cancer. NeXT Dx is a comprehensive tumor profiling test that is used to help select therapy for a cancer patient and identify potential clinical trials for a patient. The Company performed WGS on human samples for research projects, such as population sequencing initiatives. The Company’s tests and analytics are used by pharmaceutical companies for translational research, biomarker discovery, and the development of personalized cancer therapies.
Personalis Inc Info
Ticker SymbolPSNL
Company namePersonalis Inc
IPO dateJun 20, 2019
CEOHall (Christopher M)
Number of employees229
Security typeOrdinary Share
Fiscal year-endJun 20
Address6600 Dumbarton Circle
CityFREMONT
Stock exchangeNASDAQ OMX - NASDAQ BASIC
CountryUnited States of America
Postal code94555
Phone16507521300
Websitehttps://www.personalis.com/
Ticker SymbolPSNL
IPO dateJun 20, 2019
CEOHall (Christopher M)
Company Executives of Personalis Inc
Name
Name/Position
Position
Shareholding
Change
Mr. Aaron Tachibana
Mr. Aaron Tachibana
Chief Financial Officer, Chief Operating Officer
Chief Financial Officer, Chief Operating Officer
198.83K
--
Dr. Richard Chen, M.D.
Dr. Richard Chen, M.D.
Executive Vice President - Research and Development, Chief Medical Officer
Executive Vice President - Research and Development, Chief Medical Officer
171.38K
--
Ms. Lonnie Shoff
Ms. Lonnie Shoff
Independent Director
Independent Director
37.19K
+16.81%
Ms. Karin Eastham, CPA
Ms. Karin Eastham, CPA
Independent Chairman of the Board
Independent Chairman of the Board
19.76K
+31.64%
Mr. A. Blaine Bowman
Mr. A. Blaine Bowman
Independent Director
Independent Director
--
--
Mr. Stephen Moore
Mr. Stephen Moore
Senior Vice President, Chief Legal Officer, and Corporate Secretary
Senior Vice President, Chief Legal Officer, and Corporate Secretary
--
--
Mr. Woodrow A. (Woody) Myers, Jr., M.D.
Mr. Woodrow A. (Woody) Myers, Jr., M.D.
Independent Director
Independent Director
--
--
Ms. Olivia K. Bloom, CPA
Ms. Olivia K. Bloom, CPA
Independent Director
Independent Director
--
--
Mr. Christopher M. (Chris) Hall
Mr. Christopher M. (Chris) Hall
President, Chief Executive Officer, Director
President, Chief Executive Officer, Director
--
--
Dr. Kenneth Jon (Ken) Widder, M.D.
Dr. Kenneth Jon (Ken) Widder, M.D.
Independent Director
Independent Director
--
--
Name
Name/Position
Position
Shareholding
Change
Mr. Aaron Tachibana
Mr. Aaron Tachibana
Chief Financial Officer, Chief Operating Officer
Chief Financial Officer, Chief Operating Officer
198.83K
--
Dr. Richard Chen, M.D.
Dr. Richard Chen, M.D.
Executive Vice President - Research and Development, Chief Medical Officer
Executive Vice President - Research and Development, Chief Medical Officer
171.38K
--
Ms. Lonnie Shoff
Ms. Lonnie Shoff
Independent Director
Independent Director
37.19K
+16.81%
Ms. Karin Eastham, CPA
Ms. Karin Eastham, CPA
Independent Chairman of the Board
Independent Chairman of the Board
19.76K
+31.64%
Mr. A. Blaine Bowman
Mr. A. Blaine Bowman
Independent Director
Independent Director
--
--
Mr. Stephen Moore
Mr. Stephen Moore
Senior Vice President, Chief Legal Officer, and Corporate Secretary
Senior Vice President, Chief Legal Officer, and Corporate Secretary
--
--
FAQs
Who are the top five shareholders of Personalis Inc?
The top five shareholders of Personalis Inc are: Mr. Aaron Tachibana
How many institutions hold shares of Personalis Inc (PSNL)?
As of 2026Q1, 286 institutions hold shares of Personalis Inc, with a combined market value of approximately 65.32M, accounting for 62.66% of the total shares. Compared to 2025Q4, institutional shareholding has increased by 1912013.00.